[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Quantumup1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1060595604022280192.png) quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3534 followers
Created: 2025-07-23 19:49:46 UTC

H.C. Wainwright🏁 $MAZE Buy-$34 and said, "MZE782, a first-in-class SLC6A19 small molecule inhibitor for CKD can be a game changer for the stock, with the Phase X PoC data reading out in 3Q 2025.
$BMRN $PTCT $CALT $BAYZF 
H.C. Wainwright added, "Maze's proprietary COMPASS platform uniquely transforms human genetic variant information into mechanism-based drug programs, positioning the company as a leader in precision nephrology, simultaneously broadening the pipeline potential in other indications.

By functionally characterizing protective and pathogenic variants at scale, COMPASS enables ultra-targeted molecules, like MZE829 and MZE782, with best-in-class potential, tight safety profiles, and broad label expansion opportunities.

H.C. Wainwright's positive thesis is based on the following ideas:

![](https://pbs.twimg.com/media/GwkRkUeXIAANhLS.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948108297573396565/c:line.svg)

**Related Topics**
[$bayzf](/topic/$bayzf)
[$calt](/topic/$calt)
[$maze](/topic/$maze)
[$bmrn](/topic/$bmrn)
[stocks healthcare](/topic/stocks-healthcare)
[$ptct](/topic/$ptct)

[Post Link](https://x.com/Quantumup1/status/1948108297573396565)